Neoprobe Applies for Listing on NYSE

Dublin-based cancer detecting device and drug maker Neoprobe has applied for a listing on the New York Stock Exchange: Amex market.  Neoprobe is currently traded on Nasdaq’s Over the Counter Bulletin Board but the move to the NYSE would help make the company more attractive to institutional investors and provide more liquidity for existing investors.  Although it may take a number of weeks before Neoprobe is approved for the listing, Neoprobe President David C. Bupp says the listing would serve as a positive milestone for the company and would enhance shareholder value. 

Neoprobe would sell a maximum of $20 million of its own shares, while its primary investor, Platinum-Montaur Life Sciences LLC, would sell up to $31 million in shares. 

For more information, see the release from Neoprobe